The healthcare industry is increasingly becoming resource-constrained. A new generation of products and technological advances are making it challenging for companies to seek out the right investment opportunities for their businesses, investment opportunities that satisfy both societal and shareholder needs. At Arthur D. Little, we help clients realise the full value of their medical innovations by leveraging our team’s talent and industry expertise in a way that challenges traditional thinking but leads to solutions that are competitive and sustainable.
In 2013, the EU-guidelines on GDP of Medicinal Products for Human Use have been augmented: Now for example, the required storage conditions of pharmaceuticals are to be maintained during transportation. In addition, [...]
After years of low productivity, R&D in leading pharmaceutical and biotech companies is starting to deliver on its promises and the number of New Molecular Entities (NMEs) approved by the US FDA has leveled out. Once approval has been [...]
When assessing and setting R&D priorities, companies must build the necessary organizational structure and processes and launch appropriate cultural change in order to grow and profit from their technology investments. To enable our clients’ success, we apply our industry expertise in medical and pharmaceutical [...]